Advertisement
Singapore markets close in 3 hours 45 minutes
  • Straits Times Index

    3,171.12
    -16.54 (-0.52%)
     
  • Nikkei

    37,030.89
    -1,048.81 (-2.75%)
     
  • Hang Seng

    16,188.15
    -197.72 (-1.21%)
     
  • FTSE 100

    7,877.05
    +29.06 (+0.37%)
     
  • Bitcoin USD

    62,200.57
    +565.80 (+0.92%)
     
  • CMC Crypto 200

    1,288.86
    +403.32 (+44.41%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • Dow

    37,775.38
    +22.07 (+0.06%)
     
  • Nasdaq

    15,601.50
    -81.87 (-0.52%)
     
  • Gold

    2,398.00
    0.00 (0.00%)
     
  • Crude Oil

    84.44
    +1.71 (+2.07%)
     
  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     
  • FTSE Bursa Malaysia

    1,551.42
    +6.66 (+0.43%)
     
  • Jakarta Composite Index

    7,063.10
    -103.72 (-1.45%)
     
  • PSE Index

    6,411.73
    -111.46 (-1.71%)
     

Understanding bluebird bio’s Operational Performance

Understanding bluebird bio’s Operational Performance

In 2018 and 2019, bluebird bio (BLUE) is expected to generate revenues of $43.62 million and $67.0 million, respectively, compared to its revenue of $35.43 million in 2017. Meanwhile, peers Amgen (AMGN), Sarepta Therapeutics (SRPT), and Vertex Pharmaceuticals (VRTX) are expected to generate revenues of $23.36 billion, $301.13 million, and $2.99 billion, respectively, in 2018.